Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (67)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Woodward, E. R.
Right arrow Articles by Maher, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woodward, E. R.
Right arrow Articles by Maher, E. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 6, 1051-1056, Copyright © 1997 by Oxford University Press

ARTICLES

Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL

ER Woodward, C Eng, R McMahon, R Voutilainen, NA Affara, BA Ponder and ER Maher
Department of Pathology, Cambridge, UK.

Inherited predisposition to phaeochromocytoma (MIM No 171300) occurs in multiple endocrine neoplasia type 2 (MEN 2) (MIM No 171400), von Hippel- Lindau (VHL) disease (MIM No 199300), and neurofibromatosis type 1 (NF1) (MIM No 162200). In addition, familial phaeochromocytoma alone has also been reported and we and others have identified germline VHL mutations in five of six kindreds analysed previously. Germline mutations in the RET proto-oncogene, which encodes a receptor tyrosine kinase, and in the VHL tumour suppressor gene cause MEN 2 and VHL disease, respectively. To further investigate the genetics of phaeochromocytoma predisposition, we analysed three groups of patients with no evidence of VHL disease, MEN 2 or NF1: Group A, eight kindreds with familial phaeochromocytoma; Group B, two patients with isolated bilateral phaeochromocytoma; and Group C, six cases of multiple extra- adrenal phaeochromocytoma or adrenal phaeochromocytoma with a family history of neuroectodermal tumours. Germline missense VHL mutations were identified in three of eight kindreds with familial phaeochromocytoma. A germline VHL mutation was also characterised in one of the two patients with bilateral phaeochromocytoma. No VHL or RET mutations were detected in the final group of patients with multiple extra-adrenal phaeochromocytoma or adrenal phaeochromocytoma with a family history of neuroectodermal tumours. The absence of germline VHL and RET gene mutations in many of these families suggested that other phaeochromoeytoma susceptibility loci may exist. Glial cell line- derived neurotrophic factor (GDNF) has been recently identified as a natural ligand for RET. Thus, it seems plausible that GDNF is a good candidate gene to play a role in phaeochromocytoma susceptibility. We searched for germline mutations in GDNF in 16 cases of familial phaeochromocytoma (groups A, B and C) and looked for evidence of somatic change in GDNF in 28 sporadic phaeochromocytomas, 12 MEN 2 phaeochromocytomas and five VHL phaeochromocytomas. No GDNF mutations were identified in patients with familial phaeochromocytoma disease, but a c277C-->T (R93W) sequence variant was identified in one of 28 sporadic tumours. This candidate mutation was identified in the germline and tumour tissue but was not present in 104 control GDNF alleles. GDNF sequence variants including R93W have been suggested previously to represent low penetrance susceptibility mutations for Hirschsprung disease and the R93W was not identified in 376 control alleles studied by others. These findings suggest that although GDNF mutations do not appear to have a major role in the pathogenesis of familial or sporadic phaeochromocytomas, allelic variation at the GDNF locus may modify phaeochromocytoma susceptibility.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
P. Gergics, A. Patocs, M. Toth, P. Igaz, N. Szucs, I. Liko, F. Fazakas, I. Szabo, B. Kovacs, E. Glaz, et al.
Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas
Eur. J. Endocrinol., September 1, 2009; 161(3): 495 - 502.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Woodward, C. Ricketts, P. Killick, S. Gad, M.R. Morris, F. Kavalier, S. V. Hodgson, S. Giraud, B. Bressac-de Paillerets, C. Chapman, et al.
Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN
Clin. Cancer Res., September 15, 2008; 14(18): 5925 - 5930.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
E. R. Woodward, K. Wall, J. Forsyth, F. Macdonald, and E. R. Maher
VHL mutation analysis in patients with isolated central nervous system haemangioblastoma
Brain, March 1, 2007; 130(3): 836 - 842.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. J. Pollard, M. El-Bahrawy, R. Poulsom, G. Elia, P. Killick, G. Kelly, T. Hunt, R. Jeffery, P. Seedhar, J. Barwell, et al.
Expression of HIF-1{alpha}, HIF-2{alpha} (EPAS1), and Their Target Genes in Paraganglioma and Pheochromocytoma with VHL and SDH Mutations
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4593 - 4598.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E. R Woodward and E. R Maher
Von Hippel-Lindau disease and endocrine tumour susceptibility.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 415 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
E. R. Maher
Genetics of phaeochromocytoma
Br. Med. Bull., June 1, 2006; 79-80(1): 141 - 151.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Blanes, J. J. Sanchez-Carrillo, and S. J. Diaz-Cano
Topographic Molecular Profile of Pheochromocytomas: Role of Somatic Down-Regulation of Mismatch Repair
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1150 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Garber and K. Offit
Hereditary Cancer Predisposition Syndromes
J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Bryant, J. Farmer, L. J. Kessler, R. R. Townsend, and K. L. Nathanson
Pheochromocytoma: The Expanding Genetic Differential Diagnosis
J Natl Cancer Inst, August 20, 2003; 95(16): 1196 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
L. Yip, G. J. Cote, S. E. Shapiro, G. D. Ayers, C. E. Herzog, R. V. Sellin, S. I. Sherman, R. F. Gagel, J. E. Lee, and D. B. Evans
Multiple Endocrine Neoplasia Type 2: Evaluation of the Genotype-Phenotype Relationship
Arch Surg, April 1, 2003; 138(4): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
J C C Rocha, R L A Silva, B B Mendonca, S Marui, A J G Simpson, and A A Camargo
High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil
J. Med. Genet., March 1, 2003; 40(3): e31 - 31.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. R. Maher and C. Eng
The pressure rises: update on the genetics of phaeochromocytoma
Hum. Mol. Genet., October 1, 2002; 11(20): 2347 - 2354.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
B E Baysal
Hereditary paraganglioma targets diverse paraganglia
J. Med. Genet., September 1, 2002; 39(9): 617 - 622.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. P. Neumann, B. Bausch, S. R. McWhinney, B. U. Bender, O. Gimm, G. Franke, J. Schipper, J. Klisch, C. Altehoefer, K. Zerres, et al.
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
N. Engl. J. Med., May 9, 2002; 346(19): 1459 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Eketjall and C. F. Ibanez
Functional characterization of mutations in the GDNF gene of patients with Hirschsprung disease
Hum. Mol. Genet., February 1, 2002; 11(3): 325 - 329.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
M. Bahuau, A. Pelet, D. Vidaud, T. Lamireau, B. Le Bail, A. Munnich, M. Vidaud, S. Lyonnet, and D. Lacombe
GDNF as a candidate modifier in a type 1 neurofibromatosis (NF1) enteric phenotype
J. Med. Genet., September 1, 2001; 38(9): 638 - 643.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. A. Friedrich
Genotype-phenotype correlation in von Hippel-Lindau syndrome
Hum. Mol. Genet., April 1, 2001; 10(7): 763 - 767.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. D. STRIZHEVA, T. CARSILLO, W. D. KRUGER, E. J. SULLIVAN, J. H. RYU, and E. P. HENSKE
The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangiomyomatosis
Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 253 - 258.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
O. Gimm, M. Armanios, H. Dziema, H. P. H. Neumann, and C. Eng
Somatic and Occult Germ-line Mutations in SDHD, a Mitochondrial Complex II Gene, in Nonfamilial Pheochromocytoma
Cancer Res., December 1, 2000; 60(24): 6822 - 6825.
[Abstract] [Full Text]

Home page
 J. Med. Genet.Home page
F J Hes, S McKee, M J B Taphoorn, P Rehal, R B van der Luijt, R McMahon, J J van der Smagt, D Dow, R A Zewald, J Whittaker, et al.
Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only
J. Med. Genet., December 1, 2000; 37(12): 939 - 943.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
H. Le Hir, L. G. Colucci-D’Amato, N. Charlet-Berguerand, P.-F. Plouin, X. Bertagna, Vittorio de Franciscis, and C. Thermes
High Levels of Tyrosine Phosphorylated Proto-Ret in Sporadic Pheochromocytomas
Cancer Res., March 1, 2000; 60(5): 1365 - 1370.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.